Vericel Co. (NASDAQ:VCEL) Expected to Announce Earnings of -$0.15 Per Share

Equities analysts expect Vericel Co. (NASDAQ:VCEL – Get Rating) to report earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vericel’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.02). Vericel posted earnings per share of ($0.07) during the same quarter last year, which would suggest a negative year over year growth rate of 114.3%. The company is expected to issue its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Vericel will report full-year earnings of ($0.18) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.05). For the next year, analysts expect that the business will post earnings of $0.08 per share, with EPS estimates ranging from ($0.04) to $0.23. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Vericel.

Vericel (NASDAQ:VCEL – Get Rating) last announced its quarterly earnings data on Thursday, February 24th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.08). Vericel had a negative return on equity of 4.83% and a negative net margin of 4.78%. The business had revenue of $47.60 million during the quarter, compared to analysts’ expectations of $48.09 million. During the same period in the prior year, the company posted $0.25 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis.

A number of research firms have issued reports on VCEL. SVB Leerink raised their target price on Vericel from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Friday, February 25th. TheStreet lowered Vericel from a “c-” rating to a “d+” rating in a report on Thursday, March 31st. StockNews.com started coverage on Vericel in a report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Zacks Investment Research lowered Vericel from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $54.00.

Several institutional investors have recently bought and sold shares of VCEL. New York State Teachers Retirement System lifted its position in shares of Vericel by 0.9% during the 3rd quarter. New York State Teachers Retirement System now owns 45,424 shares of the biotechnology company’s stock worth $2,217,000 after buying an additional 424 shares during the period. State of New Jersey Common Pension Fund D raised its position in Vericel by 9.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 52,911 shares of the biotechnology company’s stock valued at $2,582,000 after purchasing an additional 4,614 shares during the last quarter. Maryland State Retirement & Pension System bought a new position in Vericel in the 3rd quarter valued at $902,000. Victory Capital Management Inc. raised its position in Vericel by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 268,646 shares of the biotechnology company’s stock valued at $13,110,000 after purchasing an additional 3,988 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its position in Vericel by 3.3% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 21,954 shares of the biotechnology company’s stock valued at $1,071,000 after purchasing an additional 697 shares during the last quarter.

Shares of NASDAQ VCEL traded down $1.91 during mid-day trading on Thursday, reaching $37.05. 14,372 shares of the company traded hands, compared to its average volume of 533,329. The stock has a market cap of $1.74 billion, a PE ratio of -218.76 and a beta of 1.87. The company’s fifty day moving average is $36.80 and its two-hundred day moving average is $39.62. Vericel has a fifty-two week low of $30.67 and a fifty-two week high of $68.94.

Vericel Company Profile (Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Featured Stories